- Report
- April 2025
- 175 Pages
Global
From €3958EUR$4,490USD£3,477GBP
- Report
- November 2025
- 188 Pages
Global
From €3125EUR$3,545USD£2,745GBP
€3473EUR$3,939USD£3,050GBP
- Report
- August 2025
- 192 Pages
Global
From €3125EUR$3,545USD£2,745GBP
€3473EUR$3,939USD£3,050GBP
- Report
- November 2025
Global
From €4320EUR$4,900USD£3,794GBP
- Report
- November 2025
- 200 Pages
Global
From €5607EUR$6,360USD£4,925GBP
€7009EUR$7,950USD£6,156GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €2116EUR$2,400USD£1,858GBP
€2645EUR$3,000USD£2,323GBP
- Clinical Trials
- April 2025
- 450 Pages
Global
From €3526EUR$4,000USD£3,097GBP
€4408EUR$5,000USD£3,872GBP
- Drug Pipelines
- April 2025
- 450 Pages
Global
From €3526EUR$4,000USD£3,097GBP
€4408EUR$5,000USD£3,872GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €882EUR$1,000USD£774GBP
€1102EUR$1,250USD£968GBP
- Report
- May 2025
- 110 Pages
Global
From €4188EUR$4,750USD£3,678GBP
- Report
- November 2025
- 182 Pages
Global
From €3967EUR$4,500USD£3,485GBP
- Report
- November 2025
- 150 Pages
Global
From €3394EUR$3,850USD£2,981GBP
- Report
- July 2025
- 350 Pages
Global
From €4363EUR$4,949USD£3,832GBP
- Report
- June 2025
- 180 Pages
Global
From €2821EUR$3,200USD£2,478GBP
€3526EUR$4,000USD£3,097GBP
- Report
- July 2022
- 263 Pages
Global
From €1800EUR$2,187USD£1,636GBP
- Report
- November 2021
- 222 Pages
Global
From €2645EUR$3,000USD£2,323GBP
- Report
- July 2022
- 165 Pages
Global
From €5246EUR$5,950USD£4,607GBP
- Report
- July 2024
- 100 Pages
Global
From €2645EUR$3,000USD£2,323GBP
€3306EUR$3,750USD£2,904GBP
- Report
- March 2024
- 200 Pages
Global
From €3659EUR$4,150USD£3,213GBP
- Report
- July 2023
- 145 Pages
Global
From €2777EUR$3,150USD£2,439GBP
The B Cell Maturation Antigen (BCMA) market is a subset of the oncology drugs market. BCMA is a protein found on the surface of B cells, a type of white blood cell. BCMA is a promising target for cancer immunotherapy, as it is expressed on multiple myeloma cells and other B-cell malignancies. BCMA-targeted therapies are designed to stimulate the body's immune system to recognize and attack cancer cells.
BCMA-targeted therapies are being developed by a number of companies, including Amgen, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. These companies are researching and developing BCMA-targeted therapies for multiple myeloma and other B-cell malignancies. Additionally, several clinical trials are underway to evaluate the safety and efficacy of BCMA-targeted therapies. Show Less Read more
